NCT07760883Recruiting
Metformin Effects According to SLC16A11 Carrier Status
Effect of Metformin in Individuals With Type 2 Diabetes According to SLC16A11 Risk Variant Carrier Status
Source: ClinicalTrials.gov · Last updated 12 Aug 2026
Brief summary (registry, in English)
This prospective observational study will evaluate whether the SLC16A11 risk variant influences the response to metformin in adults with type 2 diabetes. Participants will be classified as carriers or noncarriers and followed for 6 months while receiving extended-release metformin titrated to the maximum tolerated dose, between 1,500 and 2,250 mg/day. The primary outcome is the change in glycated hemoglobin, with additional assessment of seven-point capillary glucose profiles, liver enzymes, visceral fat, lipid profile, and lactate concentrations. The study plans to include 154 participants to compare treatment response between both genetic groups and explore the potential value of a more personalized therapeutic approach.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 154 (estimated)
- First submitted
- 5 Aug 2026
- Start date
- 23 Sept 2020
- Primary completion date
- 31 Jul 2027
- Lead sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Diseases
- Type 2 diabetes
- NCT number
- NCT07760883
What you commit to
- Study type: Observational
- Planned participants: 154
- From 23 Sept 2020 to the primary completion date, 31 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants receiving insulin therapy
- Concurrent participation in another research study
Other illness
- Chronic conditions such as HIV infection, cancer, or rheumatologic diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)
Lab values
- Participants receiving treatment with three glucose-lowering medications
Other
- Pregnancy
- Breastfeeding
- Body mass index (BMI) ≥45 kg/m²
Who the study is looking for
- Male and female participants
- Aged 18 to 65 years
- Diagnosis of type 2 diabetes
- Estimated glomerular filtration rate (eGFR) \>60 mL/min
- Glycated hemoglobin (HbA1c) ≤8%
- Participants who are treatment-naïve, receiving metformin monotherapy, or receiving dual glucose-lowering therapy
- Participants who agree to take part in the study
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Coordinator of this site? Confirm its status | Mexico City | Mexico | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.